RAPT Therapeutics (RAPT) Return on Sales (2020 - 2023)
Historic Return on Sales for Therapeutics (RAPT) over the last 4 years, with Q1 2023 value amounting to 109.01%.
- Therapeutics' Return on Sales fell 765900.0% to 109.01% in Q1 2023 from the same period last year, while for Mar 2023 it was 109.01%, marking a year-over-year decrease of 862800.0%. This contributed to the annual value of 56.19% for FY2022, which is 380400.0% down from last year.
- Per Therapeutics' latest filing, its Return on Sales stood at 109.01% for Q1 2023, which was down 765900.0% from 56.19% recorded in Q4 2022.
- In the past 5 years, Therapeutics' Return on Sales ranged from a high of 9.58% in Q3 2020 and a low of 109.01% during Q1 2023
- Over the past 4 years, Therapeutics' median Return on Sales value was 19.31% (recorded in 2021), while the average stood at 28.6%.
- Per our database at Business Quant, Therapeutics' Return on Sales surged by 5400bps in 2021 and then tumbled by -765900bps in 2023.
- Quarter analysis of 4 years shows Therapeutics' Return on Sales stood at 9.78% in 2020, then plummeted by -142bps to 23.72% in 2021, then plummeted by -137bps to 56.19% in 2022, then crashed by -94bps to 109.01% in 2023.
- Its last three reported values are 109.01% in Q1 2023, 56.19% for Q4 2022, and 34.73% during Q3 2022.